Mereo Biopharma Sustainability Profile
Mereo Biopharma Group plc, commonly referred to as Mereo Biopharma, is a pioneering biopharmaceutical company headquartered in Great Britain. Founded in 2015, the company focuses on developing innovative therapies for patients with rare diseases and unmet medical needs, particularly in the fields of oncology and metabolic disorders. Mereo Biopharma's core products, including its unique therapeutic candidates, are designed to address significant gaps in current treatment options, showcasing the company's commitment to advancing healthcare. With a strong emphasis on clinical development, Mereo has achieved notable milestones, including successful clinical trials that position it as a key player in the biopharma industry. As it continues to expand its operational reach, Mereo Biopharma is dedicated to delivering transformative solutions that enhance patient outcomes and solidify its market presence.
DitchCarbon Score
How does Mereo Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mereo Biopharma's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mereo Biopharma's reported carbon emissions
In 2023, Mereo Biopharma reported an employee-related carbon footprint of approximately 510 kg CO2e per employee. This figure reflects the company's ongoing commitment to understanding and managing its carbon emissions, although specific Scope 1 and Scope 2 emissions data have not been disclosed. In 2022, the company recorded a slightly lower employee-related carbon footprint of about 460 kg CO2e per employee. Mereo Biopharma has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in recognised frameworks such as the Science Based Targets initiative (SBTi). The absence of disclosed emissions data for Scope 1, Scope 2, and Scope 3 indicates a need for further transparency in their climate strategy. The company’s emissions data is not cascaded from any parent organisation, and it operates independently in its climate reporting. As Mereo Biopharma continues to grow, it may consider establishing more defined climate commitments and reduction targets to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Mereo Biopharma's Industry?
How Carbon Intensive is Mereo Biopharma's Location?
Mereo Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mereo Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
